The impact of gestational diabetes on glycation end products oxidative marker expression in placental tissue
Abstract
Objectives: The present study was designed to determine whether oxidative stress marker Advanced Glycation End products (AGEs) measurement can serve as an additional diagnostic marker of gestational diabetes, and its correlation with changes seen in placental tissue.
Methods: A case control study was designed, sixty pregnant women at third trimester between (37-41) weeks of gestation and average age between (18-45) years old were enrolled in this study. All cases selected for this study underwent elective caesarian section. Thirty healthy pregnant women at the same average of age with the same exclusion criteria were involved as control group. Patients group consist of thirty pregnant women who proved to have Gestational Diabetes (GDM) depending on OGTT and on (Soluble Insulin or Metformin) as a medication of use. All patients with family history of diabetes, hypertension, thyroid disease, renal diseases, liver diseases, cardiac problems, smoking were excluded from this study. Placental tissue samples were taken after the delivery and was immediately fixed in 10% formalin solution, prepared for Immunohistochemical study for localization of AGEs receptors.
Results: There have been marked and dramatic changes in the shape and size of placental villi in diabetic women with decrease in the number of blood vessels in the core of these villi.Fibrinoid formation is a striking feature of change seen in the placenta. AGEs antibodies showed a marked pronounced presence in trophoblastic cell of the placental villi.
Conclusion: gestational diabetes do have a recognized impact effects on placental end glycation products. There have been marked and dramatic changes in the shape and size of placental villi in diabetic women. Fibrinoid formation is a striking feature of change seen in the placenta. A marked decrease in the number of vessels in villi core in women with GDM.
References
2. Adele P., Maternal and Child Health Nursing: Care of the Childbearing and Childrearing Family, Hagerstwon, MD: Lippincott Williams & Wilkins, (2009).
3. Nilsson C., Gestational Diabetes Mellitus Future risk for mother and child, Lund University,Faculty of Medicine Doctoral Dissertation Series, (2013); 42.
4. Hannah MAC., & Narendhirakannan R.T., Oxidative Stress – A Hallmark of Human Diseases, Asian Journal of Biochemical and Pharmaceutical Research, (2012); Issue 4 (Vol. 2).
5. Kolluru GK, Bir SC, and Kevil CG. Endothelial Dysfunction and Diabetes: Effects on Angiogenesis, Vascular Remodeling, and Wound Healing. International Journal of Vascular Medicine. Volume 2012.
6. Osawa T. and Kato Y., Protective role of antioxidative food factors in oxidative stress caused by hyperglycemia, Ann N Y Acad Sci., (2005); 1043: pp. 440-51.
7. Ahmad S., Khan MS., Akhter F., Khan MS., Khan A., Ashraf JM., Pandey RP., and Shahab U., Glycoxidation of biological macromolecules: A critical approach to halt the menace of glycation, Glycobiology, (2014); 24(11):979-90.
8. Martins LG., Matos L., Soares A., Silva E. and Almeida H., AGEs, contributors to placental bed vascular changes leading to preeclampsia, Informa UK, Ltd., Free Radical Research, (2013); 47 (Suppl. 1): pp. 70-80.
9. Uribarri J. and Tuttle KR., Advanced glycation end products and nephrotoxicity of high-protein diets, Clin. J. Am. Soc. Nephrol., (2006); 1: pp. 1293-1299.
10. Del-Turco S. and Basta G., An update on advanced glycationendproducts and atherosclerosis, Biofactors, (2012); 38: pp. 266-274.
11. Mathieu JM., Schloendorn J., Rittmann BE. and Alvarez PJJ., Medical bioremediation of age-related diseases. Microbial Cell Factories, (2009); 8: 21.
12. Buongiorno AM., Morelli S., Sagratella E., Castaldo P., Di Virgilio A., Maroccia E., Ricciardi G., Sciullo E., Cardellini G., Fallucca F. andSensi M., Levels of advanced glycosylation end products (AGE) in sera of pregnant diabetic women: comparison between type 1, type 2 and gestational diabetes mellitus. Ann 1st. Super. Sanita, Vol. 33, No. 3 (1997), pp. 375-378.
13. Lappas M., Permezal M. and Rice GE., Leptin and adiponectin stimulate the release of pro-infammatory cytokines and prostaglandins from human placental and maternal adipose tissue via NF-kb, PPAR-y and ERK ½, Endocrinology, (2005); 146 pp. 3334-3342.
14. Yu Y., HanssenKF.,Kalyanaraman V., Chirindel A., Jenkins AJ. and Nankervis AJ. et al., Reduced soluble receptor for advanced glycation end products (sRAGE) scavenger capacity precedes preeclampsia in Type 1 diabetes, BJOG, (2012); 119: pp. 1512-1520.
15. Schmidt KG., Bergert H. and Funk RHW., Neurodegenerative Diseases of the Retina and Potential for Protection and Recovery, Current Neuropharmacology, Bentham Science Publishers, (2008); 6: pp. 164-178.
16. Bancroft, J. D., Floyd, A. D., & Suvarna, S. K. (2013). Bancroft's Theory and Practice of Histological Techniques,53, 83, 93, 105-121, 433-517.
17. Goh SY. and Cooper ME., The Role of Advanced Glycation End Products in Progression and Complications of Diabetes, J ClinEndocrinolMetab, (2008), 93 (4): pp. 1143-1152.
18. Zeng P., XuDL., Li Z., Lai WY. and Ren H., Effects of advanced glycation end-products on cell cycle distribution and apoptosis in neonatal rat cardiac myocytes, J South Med Univ., (2003); 23: pp. 25-27.
19. Ling X., Nagai R., Sakashita N., Takeya M., Horiuchi S. and Takahashi K., Immunohistochemical distribution and quantitative biochemical detection of advanced glycation end products in rats from fetal to adult life, Int Congress Ser., (2002); 1245: pp. 137-142.
20. Chen YC., Sheen JM., Tiao MM., Tain YL. and Huang LT., Roles of Melatonin in Fetal Programming in Compromised Pregnancies, International Journal of Molecular Sciences, (2013); 14: pp. 5380-5401.
21. Guosheng L., Hongmei S., Chuan N., Haiying L., Xiaopeng Z. and Xianqiong L. The relationship of serum AGE levels in diabetic mothers with adverse fetal outcome. Journal of Perinatology. (2009); 29: pp. 483-488.
22. Goldin A., Beckman JA., Schmidt AM. and Creager MA., Advanced Glycation End Products Sparking the Development of Diabetic Vascular Injury, American Heart Association, Inc., (2006); 114: pp. 597-605.
23. Tewari V., Tewari A. and Bhardwaj N., Histological and histochemical changes in placenta of diabetic pregnant females and its comparison with normal placenta, Asian Pacific Journal of Tropical Disease, (2011); pp. 1-4.
24. Boyanova M. &Huppertz B., Cytotoxic Effect of Advanced Glycation end Products, Biotechnology & Biotechnological Equipment, (2009); 23: 1: pp. 1072-1078.
25. Konishi H., Nakatsuka M., Chekir C., Noguchi S., Kamada Y., Sasaki A. and Hiramatsu Y., Advanced glycation end products induce secretion of chemokines and apoptosis in human ï¬rst trimester trophoblasts. Hum Reprod, (2004); 19: pp. 2156-2162.
26. Frank HG., Malekzaheh F. and Kertschanska S., Immunohistochemistry of the two different types of placental fibrinoid, ActaAratomica, (1994); 150: pp. 55-68.
27. Nelson DMI., Swanson PE. and Davison AL., Ontogenic and phylogenetic evaluation of the presence of fibrin-type fibrinoid in the villous placenta, Placenta, (1997); Sep: 18 (7): pp. 605-8.